Skip to content
OpenCapital
Get started

Outlook Therapeutics, Inc. OTLK Q3 2025 Annual earnings

Reported December 19, 2025 · Before market open

Revenue-$91.8KMiss by $5.9MDiluted EPS-$0.22Beat by $0.04
Revenue estimate$5.8M
EPS estimate-$0.26

Next report

Aug 13, 2026 (In 3 weeks)
Revenue estimate$4.8M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$128.0KMiss by $4.3MQ4 2025-$1.2MMiss by $4.4M
Q3 2025-$91.8KMiss by $5.9M
Q2 2025$1.5MMiss by $4.3M

Diluted EPS

Q1 2026-$0.16Miss by $0.04Q4 2025-$0.22Miss by $0.05
Q3 2025-$0.22Beat by $0.04
Q2 2025-$0.44Miss by $0.02Q1 2025-$0.40Beat by $0.15Q4 2024-$0.89Miss by $0.04

Ask the moment Outlook Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Outlook Therapeutics, Inc. report Q3 2025 earnings?
Outlook Therapeutics, Inc. (OTLK) reported Q3 2025 earnings on December 19, 2025 before market open.
What were Outlook Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Outlook Therapeutics, Inc. reported revenue of -$91.8K and diluted EPS of $-0.22 for Q3 2025.
Did Outlook Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $5.8M by $5.9M. EPS beat the consensus estimate of $-0.26 by $0.04.
How did Outlook Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 71.4% from $-0.77.
Where can I find Outlook Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-122786) and the 10-K periodic report (0001104659-25-123264) directly on SEC EDGAR. The filing index links above go to sec.gov.